These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26348372)

  • 21. HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy.
    Bon I; Turriziani O; Musumeci G; Clò A; Montagna C; Morini S; Calza L; Gibellini D; Antonelli G; Re MC
    J Med Virol; 2015 Feb; 87(2):315-22. PubMed ID: 25138591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
    Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
    AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic analyses reveal structured HIV-1 populations in serially sampled T lymphocytes of patients receiving HAART.
    Potter SJ; Lemey P; Dyer WB; Sullivan JS; Chew CB; Vandamme AM; Dwyer DE; Saksena NK
    Virology; 2006 Apr; 348(1):35-46. PubMed ID: 16455126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.
    Chéret A; Nembot G; Mélard A; Lascoux C; Slama L; Miailhes P; Yeni P; Abel S; Avettand-Fenoel V; Venet A; Chaix ML; Molina JM; Katlama C; Goujard C; Tamalet C; Raffi F; Lafeuillade A; Reynes J; Ravaux I; Hoën B; Delfraissy JF; Meyer L; Rouzioux C;
    Lancet Infect Dis; 2015 Apr; 15(4):387-96. PubMed ID: 25701561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic shift of env V3 loop viral sequences in patients with HIV-associated neurocognitive disorder during antiretroviral therapy.
    Eggers C; Müller O; Thordsen I; Schreiber M; Methner A
    J Neurovirol; 2013 Dec; 19(6):523-30. PubMed ID: 24101298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after long-term suppressive antiretroviral therapy in 236 patients.
    Burgard M; Boufassa F; Viard JP; Garrigue I; Ruffault A; Izopet J; Vabret A; Descamps D; Colson P; Seigneurin JM; Rouzioux C;
    AIDS; 2009 Oct; 23(16):2165-71. PubMed ID: 19657270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monotypic low-level HIV viremias during antiretroviral therapy are associated with disproportionate production of X4 virions and systemic immune activation.
    Bull ME; Mitchell C; Soria J; Styrchak S; Williams-Wietzikoski C; Legard J; McKernan-Mullin J; Kraft K; Onchiri F; Stern J; Holte S; Ryan KJ; Acosta EP; La Rosa A; Coombs RW; Ticona E; Frenkel LM
    AIDS; 2018 Jul; 32(11):1389-1401. PubMed ID: 29683841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of in vivo compartmentalization among HIV-1 infected naïve and memory CD4+ T cell subsets.
    Heeregrave EJ; Geels MJ; Brenchley JM; Baan E; Ambrozak DR; van der Sluis RM; Bennemeer R; Douek DC; Goudsmit J; Pollakis G; Koup RA; Paxton WA
    Virology; 2009 Oct; 393(1):24-32. PubMed ID: 19698967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monotypic human immunodeficiency virus type 1 genotypes across the uterine cervix and in blood suggest proliferation of cells with provirus.
    Bull ME; Learn GH; McElhone S; Hitti J; Lockhart D; Holte S; Dragavon J; Coombs RW; Mullins JI; Frenkel LM
    J Virol; 2009 Jun; 83(12):6020-8. PubMed ID: 19339344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phylogenetic Analyses Comparing HIV Sequences from Plasma at Virologic Failure to Cervix Versus Blood Sequences from Antecedent Antiretroviral Therapy Suppression.
    Bull ME; McKernan JL; Styrchak S; Kraft K; Hitti J; Cohn SE; Tapia K; Deng W; Holte S; Mullins JI; Coombs RW; Frenkel LM
    AIDS Res Hum Retroviruses; 2019 Jun; 35(6):557-566. PubMed ID: 30892052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genotypic analysis of human immunodeficiency virus type 1 env V3 loop sequences: bioinformatics prediction of coreceptor usage among 28 infected mother-infant pairs in a drug-naive population.
    Duri K; Soko W; Gumbo F; Kristiansen K; Mapingure M; Stray-Pedersen B; Muller F;
    AIDS Res Hum Retroviruses; 2011 Apr; 27(4):411-9. PubMed ID: 20969460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV sequence diversity during the early phase of infection is associated with HIV DNA reductions during antiretroviral therapy.
    Wang N; Li Y; Han Y; Xie J; Li T
    J Med Virol; 2017 Jun; 89(6):982-988. PubMed ID: 27791274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells.
    Sahu GK; Paar D; Frost SD; Smith MM; Weaver S; Cloyd MW
    J Med Virol; 2009 Jan; 81(1):9-15. PubMed ID: 19031450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analytical antiretroviral therapy interruption does not irreversibly change preinterruption levels of cellular HIV.
    Papasavvas E; Lada SM; Joseph J; Yin X; Liu Q; Azzoni L; Mounzer K; Kostman JR; Richman D; Montaner LJ
    AIDS; 2018 Aug; 32(13):1763-1772. PubMed ID: 30045057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
    Zaunders JJ; Cunningham PH; Kelleher AD; Kaufmann GR; Jaramillo AB; Wright R; Smith D; Grey P; Vizzard J; Carr A; Cooper DA
    J Infect Dis; 1999 Aug; 180(2):320-9. PubMed ID: 10395845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Dynamic changes of cellular HIV-1 DNA quantification during highly active antiretroviral therapy in Chinese HIV infected individuals].
    Chen X; Zheng Y; Mamadou D; He Y; Zhou H; Chen Z; Luo Y; He B; He M; Yao Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 May; 38(5):537-44. PubMed ID: 23719535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blood CXCR3
    Banga R; Procopio FA; Ruggiero A; Noto A; Ohmiti K; Cavassini M; Corpataux JM; Paxton WA; Pollakis G; Perreau M
    Front Immunol; 2018; 9():144. PubMed ID: 29459864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood biomarkers of expressed and inducible HIV-1.
    Cillo AR; Hong F; Tsai A; Irrinki A; Kaur J; Sloan DD; Follen M; Geleziunas R; Cihlar T; Win SS; Murry JP; Mellors JW
    AIDS; 2018 Mar; 32(6):699-708. PubMed ID: 29334544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy.
    Brennan TP; Woods JO; Sedaghat AR; Siliciano JD; Siliciano RF; Wilke CO
    J Virol; 2009 Sep; 83(17):8470-81. PubMed ID: 19535437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations.
    Rozera G; Abbate I; Bruselles A; Vlassi C; D'Offizi G; Narciso P; Chillemi G; Prosperi M; Ippolito G; Capobianchi MR
    Retrovirology; 2009 Feb; 6():15. PubMed ID: 19216757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.